当前位置: X-MOL 学术ACS Nano › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
E. coli Membrane Vesicles as a Catalase Carrier for Long-Term Tumor Hypoxia Relief to Enhance Radiotherapy
ACS Nano ( IF 15.8 ) Pub Date : 2021-09-14 , DOI: 10.1021/acsnano.1c07621
Wenjing Zai 1 , Lin Kang 1 , Tiejun Dong 1 , Haoran Wang 1 , Lining Yin 1 , Shaoju Gan 1 , Wenjia Lai 2 , Yibing Ding 1 , Yiqiao Hu 1, 3 , Jinhui Wu 1, 3, 4
Affiliation  

Hypoxia is one of the most important factors that limit the effect of radiotherapy, and the abundant H2O2 in tumor tissues will also aggravate hypoxia-induced radiotherapy resistance. Delivering catalase to decompose H2O2 into oxygen is an effective strategy to relieve tumor hypoxia and radiotherapy resistance. However, low stability limits catalase’s in vivo application, which is one of the most common limitations for almost all proteins’ internal utilization. Here, we develop catalase containing E. coli membrane vesicles (EMs) with excellent protease resistance to relieve tumor hypoxia for a long time. Even treated with 100-fold of protease, EMs showed higher catalase activity than free catalase. After being injected into tumors post 12 h, EMs maintained their hypoxia relief ability while free catalase lost its activity. Our results indicate that EMs might be an excellent catalase delivery for tumor hypoxia relief. Combined with their immune stimulation features, EMs could enhance radiotherapy and induce antitumor immune memory effectively.

中文翻译:

大肠杆菌膜囊作为过氧化氢酶载体用于长期缓解肿瘤缺氧以增强放射治疗

缺氧是限制放疗效果的最重要因素之一,肿瘤组织中丰富的H 2 O 2也会加剧缺氧诱导的放疗抵抗。递送过氧化氢酶将H 2 O 2分解成氧气是缓解肿瘤缺氧和放疗抵抗的有效策略。然而,低稳定性限制了过氧化氢酶的体内应用,这是几乎所有蛋白质内部利用的最常见限制之一。在这里,我们开发了含有大肠杆菌的过氧化氢酶膜囊泡(EMs)具有优异的蛋白酶抗性,可长期缓解肿瘤缺氧。即使用 100 倍的蛋白酶处理,EM 也显示出比游离过氧化氢酶更高的过氧化氢酶活性。在 12 小时后注射到肿瘤中后,EMs 保持了它们的缺氧缓解能力,而游离过氧化氢酶失去了活性。我们的结果表明,EMs 可能是缓解肿瘤缺氧的一种极好的过氧化氢酶递送。结合它们的免疫刺激特性,EMs可以有效地增强放射治疗并诱导抗肿瘤免疫记忆。
更新日期:2021-09-28
down
wechat
bug